Profile of ABCELLERA BIOLOGICS INC(NASDAQ:ABCL) stock

ABCELLERA BIOLOGICS INC10.97

NASDAQ:ABCL (2/6/2023, 7:00:00 PM)-0.21 (-1.88%)

After market: 10.96 -0.01 (-0.09%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Life Sciences Tools & Services

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-08 2022-11-08/amc	Earnings (Next)	02-21 2023-02-21/amc
Ins Owners	20.37%	Inst Owners	48.58%
Market Cap	3.14B	Shares	286.10M
PE	13.89	Fwd PE	N/A
Dividend Yield	N/A	Analysts	83.75
IPO	12-11 2020-12-11

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company rebuilds the platform that integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. The firm partners with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

Company Info

ABCELLERA BIOLOGICS INC

2215 Yukon Street

Vancouver BRITISH COLUMBIA

P: 16045599005.0

Employees: 386

Website: https://www.abcellera.com/

ABCL News

5 days ago - InvestorPlaceThe 7 Most Undervalued Biotech Stocks to Buy in February 2023

Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.

5 days ago - Seeking AlphaLLY stock slips as falling demand for COVID therapy hurts topline (NYSE:LLY)

Eli Lilly (LLY) fell in the pre-market Thursday after reporting lower than expected revenue for Q4 2022 as demand for its COVID-19 therapy continued to plunge. Read the full story here.